PROTAC Bromodomain Inhibitor ARV-825 Displays Anti-Tumor Activity in Neuroblastoma by Repressing Expression of MYCN or c-Myc

  • Front Oncol. 2020 Nov 26:10:574525. doi: 10.3389/fonc.2020.574525.
Zhiheng Li  1  2 ,  Su Lin Lim  3 ,  Yanfang Tao  1 ,  Xiaolu Li  1 ,  Yi Xie  1 ,  Chun Yang  1 ,  Zimu Zhang  1 ,  You Jiang  4 ,  Xianbing Zhang  5 ,  Xu Cao  6 ,  Hairong Wang  1 ,  Guanghui Qian  1 ,  Yi Wu  7 ,  Mei Li  1 ,  Fang Fang  1 ,  Ying Liu  1 ,  Mingcui Fu  6 ,  Xin Ding  8 ,  Zhenghong Zhu  9 ,  Haitao Lv  10 ,  Jun Lu  4 ,  Sheng Xiao  2 ,  Shaoyan Hu  1  4 ,  Jian Pan  1
Affiliations
  • 1. Institute of Pediatric Research, Children's Hospital of Soochow University, Suzhou, China.
  • 2. Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.
  • 3. Department of Internal Medicine, Saint Michael's Medical Center, Newark, NJ, United States.
  • 4. Department of Hematology, Children's Hospital of Soochow University, Suzhou, China.
  • 5. Department of Pediatric Surgery, The First People's Hospital of Kunshan, Suzhou, China.
  • 6. Department of Pediatric Surgery, Children's Hospital of Soochow University, Suzhou, China.
  • 7. Department of Pathology, Children's Hospital of Soochow University, Suzhou, China.
  • 8. Department of Neonatology, Children's Hospital of Soochow University, Suzhou, China.
  • 9. Department of Burn and Plastic Surgery, Children's Hospital of Soochow University, Suzhou, China.
  • 10. Department of Cardiology, Children's Hospital of Soochow University, Suzhou, China.
Abstract

Neuroblastoma (NB) is one of the most common solid Tumors in childhood. To date, targeting MYCN, a well-established driver gene in high-risk Neuroblastoma, is still challenging. In recent years, inhibition of bromodomain and extra terminal (BET) proteins shows great potential in multiple of Myc-driven Tumors. ARV-825 is a novel BET Inhibitor using proteolysis-targeting chimera (PROTAC) technology which degrades target proteins by the Proteasome. In this study, we investigated the effect of ARV-825 in Neuroblastoma in vitro and in vivo. Our results showed that ARV-825 treatment robustly induced proliferative suppression, cell cycle arrest, and Apoptosis in NB cells. Moreover, ARV-825 efficiently depleted BET protein expression, subsequently repressing the expression of MYCN or c-Myc. In the NB xenograft model, ARV-825 profoundly reduced tumor growth and led to the downregulation of BRD4 and MYCN expression in mice. Taken together, these findings provide evidence that PROTAC BET Inhibitor is an efficient way to achieve MYCN/c-Myc manipulation, and ARV-825 can be used as a potential therapeutic strategy for the treatment of Neuroblastoma.

Keywords
ARV-825; BRD4; MYCN; c-Myc; neuroblastoma.